

**AMENDMENTS TO THE CLAIMS**

1-48. (canceled)

49. (currently amended): An isolated or recombinant polypeptide ~~[[ef]] having SEQ ID NO: 3, 5, or 7-12 or encoded by a nucleotide sequence of SEQ ID NO: 2, 4, or 6 or fragment or variant thereof wherein the fragment or variant induces a specific antibody response.~~

50-53. (canceled)

54. (currently amended): ~~[[The]] A fragment of a polypeptide of claim 49 consisting of at least nine, ten, or fifteen contiguous amino acids of the polypeptide, wherein the fragment induces a specific antibody response.~~

55. (currently amended): The polypeptide of claim 49 ~~fragment of claim 54~~ comprising one or more immunoreactive epitope(s).

56. (currently amended): The polypeptide ~~fragment of claim 54 comprising consisting~~ of the polypeptide of any of Tables VIII to XLIX.

57. (currently amended): ~~An immunogenic A~~ composition which comprises the polypeptide of claim 49 ~~in admixture with at least one and a pharmaceutically acceptable excipient carrier.~~

58. (currently amended): A method of generating an immune response in a mammalian subject comprising exposing cells of the mammal's immune system to ~~an amount of the a polypeptide of claim 49 sufficient to generate said having SEQ ID NO: 3, 5, or 7, whereby an immune response to the polypeptide is generated.~~

59. (previously presented): The method of claim 58 wherein the polypeptide has at least one T cell or at least one B cell epitope.

60. (currently amended): The method of ~~claim 59~~ claim 58 wherein the immune response comprises ~~an individual~~ activation of a B cell that generates antibodies that specifically bind to the polypeptide.

61. (currently amended): The method of ~~claim 60~~ claim 58 wherein the immune ~~response~~ comprises activating a T cell that is a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the polypeptide.

62. (currently amended): The method of ~~claim 60~~ claim 58 wherein the immune response comprises activating ~~a T cell that is~~ a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody-producing activity of a B cell.

63. (previously presented): A polynucleotide that encodes the polypeptide of claim 49 or is fully complementary to the polynucleotide wherein T can also be U.

64-65. (canceled)

66. (currently amended): The polynucleotide of claim 63 having SEQ ID NO: 2, 4, or 6, ~~or a nucleotide sequence encoding SEQ ID NO: 3, 5, or 7-12.~~

67-71. (canceled)

72. (currently amended): An isolated host cell modified to contain an expression vector for expressing the polynucleotide of claim 63 ~~and capable of producing a polypeptide encoded by the polynucleotide.~~

73-74. (canceled)

75. (currently amended): A method for ~~monitoring expression levels of a polypeptide of claim 49 or mRNA which encodes said polynucleotide in a biological sample from a subject who~~

~~has or is suspected of having~~ detecting the presence of cancer versus a normal sample in an individual comprising:

~~determining the level of [[the]] expression of a polypeptide or mRNA expressed by cells in a biological sample from the subject having SEQ ID NO: 3, 5, or 7 in a test sample from an individual; and~~

~~determining comparing the level so determined to the level of expression that is evidenced in a of the polypeptide or mRNA expressed by cells in a corresponding normal sample,~~

~~wherein the elevated expression of said polypeptide in the test sample versus the ; and~~

~~comparing the levels of the polypeptide or mRNA determined in the biological sample to the level of the polypeptide or mRNA determined in the corresponding normal sample is an indication of the presence of cancer.~~

76. (canceled)

77. (currently amended): The method of ~~claim 76~~ claim 75 wherein the cancer occurs in ~~a tissue which is lung or~~ is selected from the group of cancers consisting of lung, ovary, breast pancreas, and prostate.

78. (canceled)

79. (new): The method of claim 58, wherein the polypeptide is expressed in a viral vector.

80. (new): The method of claim 79 wherein the viral vector is selected from the group consisting of vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbis virus.